Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Hitting Cancer Where It Hurts
Two studies in the May 29th issue of Cell, a Cell Press publication, have taken advantage of new technological advances to search for and find previously unknown weaknesses in a hard to treat form of cancer. The discoveries lend new hope in the fight again tumors that are today considered "undruggable."
generic viagra online
New Global Subsidy For Malaria Medicines Must Ensure Quality Of Care
A new subsidy designed to increase access to life-saving antiretrovirals
News of the day
HIV/AIDS Advocates React To Obama's Proposed Global Health Initiative
Some HIV/AIDS advocates have voiced disappointment with the level of HIV/AIDS funding in President Obama"s proposed $63 billion, six-year global health initiative, VOA News reports. According to VOA News, the advocates say that Obama has not met pledges he made as a presidential candidate, while other say that the "picture is more complicated." According to the Global AIDS Alliance, Obama previously pledged to dedicate $50 billion over five years to HIV/AIDS, TB and malaria, but has instead proposed $51 billion over six years. GAA Executive Director Paul Zeitz said this proposal translates into significantly less annual funding for PEPFAR (Kilner, VOA News, 5/19). Zeitz said, "President Obama has a moral obligation to demonstrate global leadership on behalf of the poorest and most marginalized people of the world, especially in Africa," adding, "But by turning his back on those needs, the president is betraying the trust of tens of millions of people" (Pflanz, Daily Telegraph, 5/18). Advocates estimate that the funding shortfall could result in about one million people going without HIV/AIDS treatment and about 2.9 million women going without treatment to prevent mother-to-child HIV transmission. James Kamau, coordinator for the Kenya Treatment Action Movement, said that one effect of Obama"s proposal is that other donor countries could take similar actions, leading to additional cuts. "In Kenya here we say when the lead sheep limps then it does not get the others to the pastures," Kamau said, adding, "Now if [Obama] cuts back funding on the Global Fund, then the rest of the people will follow suit" (VOA News, 5/19). Some have welcomed Obama"s proposal, saying that it has expanded the focus of global health initiatives to include other health issues that can be treated at a low cost but have not received as much attention, VOA News reports. Obama"s proposal includes $12 billion for these additional areas of focus, including more emphasis on maternal health and health infrastructure, according to VOA News.According to VOA News, Obama"s proposal might be more than Congress is willing to allocate during the economic crisis. The current budget resolution under consideration by Congress would allocate $51 billion for foreign aid in FY 2010, almost $3 billion less than what Obama requested (VOA News, 5/18). African Government Spending on Health
Health Insurance

Revance Therapeutics Announces Efficacy Of Topical Botulinum Toxin Type A For The Treatment Of Facial Wrinkles

Revance Therapeutics, Inc. ("Revance") announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow"s feet wrinkles, demonstrated efficacy and safety in a US Phase 2b clinical study. The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo at primary and multiple secondary endpoints. This is the most recent Phase 2 study to demonstrate the efficacy of RT001 and the results are consistent with earlier Phase 2 studies conducted in the US and internationally. More than 200 patients have been treated with RT001 and it has been safe and well tolerated. "The benefits of RT001 are clear; patients achieve meaningful aesthetic results with a simple, painless procedure" said Richard Glogau, MD, Clinical Professor of Dermatology at University of California, San Francisco and principal investigator for the study, "The superficial muscles in the crow"s feet area can be relatively difficult to inject; this treatment will allow physicians to obtain a more consistent result while maintaining patients" natural expressions". Fredric Brandt, MD, who also participated in the study agrees, "RT001 represents a natural evolution in the treatment regimen which will appeal to a whole new segment of patients who want the cosmetic benefit but are unwilling to tolerate the discomfort and bruising caused by multiple injections". "We are very pleased with our progress and the data generated from our Phase 2 clinical program," commented Dan Browne, President and CEO of Revance, "It represents an important milestone for the company as we proceed to our End of Phase 2 meeting with the FDA later this year. I want to thank all the US and international Phase 2 Investigators and their clinical research teams for their efforts to achieve this milestone." About RT001 RT001, Botulinum Toxin Type A Topical Gel, an investigational product, is designed to reduce crow"s feet wrinkles by temporarily relaxing the muscles around the eye. Unlike other procedures that require several injections in the sensitive periorbital area, RT001 gel is simply applied by the physician and then wiped off after the procedure. Revance"s goal is to expand the market beyond other injectable treatments like Botox® Cosmetic, which despite their popularity, have only captured about 10% of the market. The Company believes that offering a safe, efficacious and painless procedure will appeal to the 9 out of 10 consumers who have considered treatment but are uncomfortable with the pain and bruising associated with injectables. RT001 is currently being studied for the treatment of lateral canthal lines (crow"s feet) and hyperhidrosis (excessive sweating). Revance Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009